BioSpace News Archive

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds of $45,500,000.

Danaher Corporation announced that it has priced an offering of $1,000,000,000 principal amount of 2.800% senior notes due 2051 at an offering price of 99.396% of the principal amount.

Moderna, Inc. (Nasdaq: MRNA), today announced a revised supply agreement with the UK government for up to 60 million doses of Moderna’s COVID-19 vaccine, which may include authorized booster vaccine candidates, with up to 29 million doses expected to be delivered in 2022 and up to 31 million doses expected to be delivered in 2023.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced the publication of the interim results from REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) in the New England Journal of Medicine Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group. REVERSE-IT is PhaseBio’s ongoing pivotal Phase 3 trial of its lead product bentracimab.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021.

Pulmotect, Inc., a clinical-stage biotechnology company, announced results from the second of two Phase 2 clinical trials undertaken in the United States with the support of the U.S. Department of Defense to evaluate PUL-042 against COVID-19.

Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services.

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase 2 Trial (designated “M201”) for OT-101, the Company’s TGF-β inhibitor, in combination with Anti-PD-1 (Pembrolizumab/Keytruda®) as a treatment for patients with Malignant Pleural Mesothelioma (MPM).

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, today announced the Company has received approval by Medical Devices Control Division for FDA Thailand to import and commercialize INVOcell in Thailand.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of Inspection.